Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

  • End date
    May 29, 2028
  • participants needed
  • sponsor
    Sanofi Pasteur, a Sanofi Company
Updated on 29 May 2022
Accepts healthy volunteers


Primary Objective:

To assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women vaccinated with MenQuadfi® during pregnancy or in the 30 days preceding their Last Menstrual Period (LMP).


This study is a prospective pregnancy registry to collect and analyze the outcome of exposure to MenQuadfi™ during pregnancy or within 30 days prior to their LMP. The registry will encourage prospective registration, which is defined as registration of a pregnancy exposure prior to knowledge or perceived knowledge of the pregnancy outcome.

Exposed pregnant women will be followed up to the end of their pregnancy, and the offspring(s) will be followed up to 1 year of age.

Condition Meningococcal Infection
Treatment Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Clinical Study IdentifierNCT04843111
SponsorSanofi Pasteur, a Sanofi Company
Last Modified on29 May 2022


Yes No Not Sure

Inclusion Criteria

The eligible population will include pregnant women and their offspring residing in the US
and its territories who are exposed to MenQuadfi® during their pregnancy or within 30 days
prior to their LMP, for whom the exposure is reported to the pregnancy registry
Reports of MenQuadfi® pregnancy exposure must contain the following information
Sufficient evidence to confirm that vaccination occurred during the pregnancy or in
the 30 days preceding the LMP
Vaccine name (brand or generic) is provided (i.e., MenQuadfi®, Meningococcal vaccine
MenACWY conjugate vaccine), or not specified (eg, meningococcal vaccine from an
unknown manufacturer)

Exclusion Criteria

Only post-marketing spontaneous case reports will be included; reports from clinical trials
will not be part of the registry
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note